Diligence memo · auto-generated · as of July 2, 2026
Nutrivert Inc.
Nutrivert Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Nutrivert Inc. operates in Pharmaceuticals, based in ATLANTA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Nutrivert Inc. has raised $1.5M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.5M on 2023-03-08.
Most recent recorded round closed around 2023-03-08.
Valuation (modeled)modeled
Provath models Nutrivert Inc. at approximately $14M (range $1.1M–$54M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.47× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era. Within the normal band (147% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 3.3 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 24% of Pharmaceuticals peers (1610 compared).
Modeled value ranks above 22% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.